Clinical Trial Update: A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 1/2 study of CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2 knockout plus lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Malignancies

Drugs mentioned

• CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2 knockout

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloid Malignancies | Phase 1, Phase 2 | Status: RECRUITING